Lucid Diagnostics Inc. (LUCD)

0.6831 -0.0399 (-5.52%) At close: 04:00PM EDT

Lucid Diagnostics Inc.

360 Madison Avenue
25th Floor
New York, NY 10017
United States
917 813 1828
https://www.luciddx.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 70

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Lishan Aklog M.D.	Chairman & CEO	N/A	N/A	1966
Mr. Shaun M. O'Neill M.B.A.	President & COO	N/A	N/A	1983
Mr. Dennis M. McGrath CPA	Chief Financial Officer	N/A	N/A	1957
Dr. Sanford D. Markowitz M.D., Ph.D.	Cofounder & Strategic Advisor, Member of the Medical Advisor Board	14.54k	N/A	N/A
Dr. Joseph Willis M.D.	Cofounder, Strategic Advisor & Member of Medical Advisory Board	N/A	N/A	N/A
Dr. Amitabh Chak M.D.	Cofounder, Strategic Advisor & Member of Medical Advisory Board	N/A	N/A	N/A
Richard D. Yazbeck	Chief Technology Officer	N/A	N/A	N/A
Dr. Suman M. Verma M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Dr. Brian J. deGuzman M.D.	Chief Compliance Officer	N/A	N/A	1965
Mr. Michael Adam Gordon	General Counsel & Secretary	N/A	N/A	1974

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Corporate governance

Lucid Diagnostics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.